Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

48.49 +0.29 (+0.60%)
Streaming Delayed Price Updated: 2:43 PM EST, Dec 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
34 35 Next >
News headline image
Should You Buy This Biotech Stock That Just Gained 5% in 1 Day? ↗
The comeback may have begun. 
Via The Motley Fool
News headline image
Pharma Bro Martin Shkreli Shorts Olema Pharmaceuticals Stock ↗
"Pharma Bro' and notorious bear Martin Shkreli is shorting Olema Pharmaceuticals stock. 
Via Benzinga
News headline image
OLMA Stock Doubles After Roche Cancer Drug Trial Yields Positive Results ↗
Roche was evaluating Giredestrant as an adjuvant endocrine treatment for people with certain types of early-stage breast cancer. 
Via Stocktwits
News headline image
Cancer Focused Olema Pharmaceuticals Stock Soars 150% - Here's Why ↗
Roche posts positive phase 3 results for giredestrant in early breast cancer, showing improved disease-free survival and a favorable safety profile. 
Via Benzinga
News headline image
Why Roche's Positive Test Results Sent Olema Pharma Skyrocketing 200% ↗
The companies are both working on oral selective estrogen receptor degraders, which break down the estrogen cancer cells need to grow. 
Via Investor's Business Daily
Topics Government
News headline image
2 No-Brainer Healthcare Stocks to Buy Now ↗
These two healthcare stocks scan as bargains right now. 
Via The Motley Fool
News headline image
Genentech’s Giredestrant Becomes the First Oral SERD to Show Superior Invasive Disease-Free Survival in Early Breast Cancer
From Genentech
Via Business Wire
News headline image
Magnificent Seven Will Become Low-Profit Tech Utilities, Analyst Warns ↗
Magnificent Seven, beware. Kai Wu says Wall Street's AI darlings are shifting toward a riskier, capital-heavy model. 
Via Benzinga
Topics Artificial Intelligence
News headline image
Jazz, Zymeworks Catapult On Their 'Sweeping Success' In Gastric Cancer ↗
Shares of Jazz Pharmaceuticals and Zymeworks catapulted Monday on positive test results for a gastric cancer drug. 
Via Investor's Business Daily
News headline image
Why Roche Holding Stock Popped Today ↗
Roche is great at developing drugs -- but is its stock a great buy? 
Via The Motley Fool
News headline image
TG Therapeutics Crumbles After Roche Unveils Its 'Unprecedented' Test Results ↗
Roche presented "unprecedented" test results for its multiple sclerosis treatment, putting pressure on rival TG Therapeutics. 
Via Investor's Business Daily
News headline image
Multimodal AI Unleashes New Era in Cancer Research: A Revolution in Diagnosis and Treatment
Recent breakthroughs in multimodal Artificial Intelligence (AI) are fundamentally reshaping the landscape of cancer research, ushering in an era of unprecedented precision in diagnosis and personalized... 
Via TokenRing AI
Topics Artificial Intelligence
News headline image
Genentech’s Fenebrutinib Shows Unprecedented Positive Phase III Results as the Potential First and Only BTK Inhibitor in Both Relapsing and Primary Progressive Multiple Sclerosis
From Genentech
Via Business Wire
News headline image
Celcuity Eyeing Cancer Treatment Riddle. Stock Flys 534% This Year. ↗
The company hopes to "solve a 20-year riddle" in cancer treatment. The journey has sent the biotech stock flying as much as 534%. 
Via Investor's Business Daily
News headline image
AI Unleashes a New Era in Cell and Gene Therapy: A Quarter Century Update Reveals Transformative Potential
The burgeoning fields of cell and gene therapy (CGT) are on the cusp of a profound revolution, driven by the relentless advancements in artificial intelligence. This transformative impact was a central... 
Via TokenRing AI
Topics Artificial Intelligence
News headline image
Genentech to Present New Data From Its Broad and Innovative Hematology Portfolio at ASH 2025
From Genentech
Via Business Wire
News headline image
Positive Phase III Data for Genentech’s Gazyva Show Significant Reduction in Disease Activity for Systemic Lupus Erythematosus
From Genentech
Via Business Wire
News headline image
AI: The Pharmaceutical Sector’s New Catalyst for a Healthier Future
The pharmaceutical industry is in the midst of a profound and rapid transformation, driven by the pervasive integration of Artificial Intelligence (AI). What was once a futuristic concept is, by late... 
Via TokenRing AI
Topics Animal Testing Artificial Intelligence Economy
News headline image
Positive Phase III Results for Genentech’s Gazyva in Children and Young Adults With Idiopathic Nephrotic Syndrome
From Genentech
Via Business Wire
News headline image
Top 3 Health Care Stocks You'll Regret Missing In October ↗
 
Via Benzinga
News headline image
Exelixis Stock Falls After Phase 3 Colorectal Cancer Trial Shows Mixed Results ↗
Exelixis stock dips after Phase 3 data show modest survival gains from zanzalintinib and Tecentriq combo in colorectal cancer patients. 
Via Benzinga
News headline image
S&P 500's Resurgence: A Deep Dive into Market Dynamics and Future Trajectories
The S&P 500 has staged a remarkable rebound, soaring to unprecedented highs in late 2025 following a period of significant sell-off earlier in the year. This resurgence, driven by a powerful confluence... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
News headline image
Top 1% Celcuity Shoots To Record High On Roche-Rivaling Breast Cancer Results ↗
The company said its breast cancer treatment delayed progression for a median of 19.7 months in some patients. 
Via Investor's Business Daily
Topics Government
News headline image
Rapt Therapeutics, Outperforming 98% Of All Stocks, Skyrockets After Topping Roche ↗
The company took on Roche's Xolair in a 16-week study of patients with a chronic hives disorder. 
Via Investor's Business Daily
News headline image
Genentech’s Tecentriq Showed Significant Overall and Disease-Free Survival Benefits in Bladder Cancer With ctDNA-Guided Treatment
From Genentech
Via Business Wire
News headline image
FDA Approves Genentech’s Gazyva for the Treatment of Lupus Nephritis
From Genentech
Via Business Wire
News headline image
Genentech’s Phase III evERA Data Showed Giredestrant Significantly Improved Progression-Free Survival in People With ER-Positive Advanced Breast Cancer
From Genentech
Via Business Wire
News headline image
Genentech Presents New Phase III Pivotal Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss
From Genentech
Via Business Wire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: 89bio, Inc. (Nasdaq - ETNB), Barinthus Biotherapeutics plc (Nasdaq - BRNS), Verint Systems Inc. (Nasdaq - VRNT), Dayforce, Inc. (NYSE- DAY)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Small-Cap Biotech Climb Bio's Lead Drug Candidate Has Larger Long-Term Opportunity ↗
William Blair assigns Climb Bio an Outperform rating, projecting peak sales of $1.9 billion and long-term growth for its therapy pipeline. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
34 35 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.